163 related articles for article (PubMed ID: 35857766)
21. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response.
Qi X; Yang M; Ma L; Sauer M; Avella D; Kaifi JT; Bryan J; Cheng K; Staveley-O'Carroll KF; Kimchi ET; Li G
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115942
[TBL] [Abstract][Full Text] [Related]
22. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
[TBL] [Abstract][Full Text] [Related]
23. Pulsed Electric Field Ablation versus Radiofrequency Thermal Ablation in Murine Breast Cancer Models: Anticancer Immune Stimulation, Tumor Response, and Abscopal Effects.
Pastori C; Nafie EHO; Wagh MS; Mammarappallil JG; Neal RE
J Vasc Interv Radiol; 2024 Mar; 35(3):442-451.e7. PubMed ID: 38042523
[TBL] [Abstract][Full Text] [Related]
24. Epimorphin deletion inhibits polyposis in the Apcmin/+ mouse model of colon carcinogenesis via decreased myofibroblast HGF secretion.
Swietlicki EA; Bala S; Lu J; Shaker A; Kularatna G; Levin MS; Rubin DC
Am J Physiol Gastrointest Liver Physiol; 2013 Oct; 305(8):G564-72. PubMed ID: 23886856
[TBL] [Abstract][Full Text] [Related]
25. HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells.
Matsumura A; Kubota T; Taiyoh H; Fujiwara H; Okamoto K; Ichikawa D; Shiozaki A; Komatsu S; Nakanishi M; Kuriu Y; Murayama Y; Ikoma H; Ochiai T; Kokuba Y; Nakamura T; Matsumoto K; Otsuji E
Int J Oncol; 2013 Feb; 42(2):535-42. PubMed ID: 23233163
[TBL] [Abstract][Full Text] [Related]
26. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
[TBL] [Abstract][Full Text] [Related]
27. Profile of serum factors and disseminated tumor cells before and after radiofrequency ablation compared to resection of colorectal liver metastases - a pilot study.
Hinz S; Tepel J; Röder C; Kalthoff H; Becker T
Anticancer Res; 2015 May; 35(5):2961-7. PubMed ID: 25964582
[TBL] [Abstract][Full Text] [Related]
28. Oncogenesis: An "Off-Target" Effect of Radiofrequency Ablation.
Rozenblum N; Zeira E; Scaiewicz V; Bulvik B; Gourevitch S; Yotvat H; Galun E; Goldberg SN
Radiology; 2015 Aug; 276(2):426-32. PubMed ID: 26203709
[TBL] [Abstract][Full Text] [Related]
29. Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma.
Ke S; Ding XM; Kong J; Gao J; Wang SH; Cheng Y; Sun WB
J Transl Med; 2010 Jul; 8():73. PubMed ID: 20667141
[TBL] [Abstract][Full Text] [Related]
30. Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells.
Hung W; Elliott B
J Biol Chem; 2001 Apr; 276(15):12395-403. PubMed ID: 11278729
[TBL] [Abstract][Full Text] [Related]
31. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells.
Sulpice E; Ding S; Muscatelli-Groux B; Bergé M; Han ZC; Plouet J; Tobelem G; Merkulova-Rainon T
Biol Cell; 2009 Sep; 101(9):525-39. PubMed ID: 19281453
[TBL] [Abstract][Full Text] [Related]
32. Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor.
Zlot C; Ingle G; Hongo J; Yang S; Sheng Z; Schwall R; Paoni N; Wang F; Peale FV; Gerritsen ME
J Biol Chem; 2003 Nov; 278(48):47654-9. PubMed ID: 14500721
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613
[TBL] [Abstract][Full Text] [Related]
34. In vivo detection of distal tumor glycolytic flux stimulated by hepatic ablation in a breast cancer model using hyperpolarized
Goodwin JS; Tsai LL; Mwin D; Coutinho de Souza P; Dialani S; Moon JT; Zhang Z; Grant AK; Ahmed M
Magn Reson Imaging; 2021 Jul; 80():90-97. PubMed ID: 33901585
[TBL] [Abstract][Full Text] [Related]
35. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis.
Kim WH; Matsumoto K; Bessho K; Nakamura T
Am J Pathol; 2005 Apr; 166(4):1017-28. PubMed ID: 15793283
[TBL] [Abstract][Full Text] [Related]
36. Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs.
Onimaru M; Yonemitsu Y; Tanii M; Nakagawa K; Masaki I; Okano S; Ishibashi H; Shirasuna K; Hasegawa M; Sueishi K
Circ Res; 2002 Nov; 91(10):923-30. PubMed ID: 12433837
[TBL] [Abstract][Full Text] [Related]
37. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
[No Abstract] [Full Text] [Related]
38. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
[TBL] [Abstract][Full Text] [Related]
39. Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
Aldahl J; Mi J; Pineda A; Kim WK; Olson A; Hooker E; He Y; Yu EJ; Le V; Lee DH; Geradts J; Sun Z
J Biol Chem; 2020 Jan; 295(2):631-644. PubMed ID: 31819003
[TBL] [Abstract][Full Text] [Related]
40. Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition.
Okayama K; Azuma J; Dosaka N; Iekushi K; Sanada F; Kusunoki H; Iwabayashi M; Rakugi H; Taniyama Y; Morishita R
Hypertension; 2012 May; 59(5):958-65. PubMed ID: 22392903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
